Science Corporation, a brain-computer interface firm headquartered in the United States, announced a $400m Series D funding round on Tuesday via a blog post. The financing brings the company's total capital raised since its 2021 founding to more than $900m.

The round attracted backing from Khosla Ventures, Tenet Healthcare, Y Combinator, 885 Capital, PLC Neurotech and the Ackman Oxman Institute, among other investors. The company declined to identify a lead investor or reveal its current valuation.

This funding follows a $230m Series C round completed eight months earlier, which TechCrunch reported valued Science Corporation at $1.5bn.

Max Hodak, who previously served as co-founder and president at Neuralink, leads the company. Its flagship offering, PRIMA, consists of a microscopic implant positioned beneath the retina that pairs with specialized camera glasses. The device targets individuals experiencing central vision loss from geographic atrophy, an advanced form of dry age-related macular degeneration.

PRIMA obtained CE mark approval in July, enabling the company to commercialize the device across 30 European nations. According to Science Corporation, it represents the first brain-computer interface bearing CE mark certification capable of restoring form vision—the capacity to perceive letters, numerals and written text.

The company intends to deploy the fresh capital toward expanding PRIMA's availability throughout Europe and advancing toward a United States market entry. The US strategy involves pursuing FDA clearance via the Humanitarian Device Exemption pathway, designed for medical devices serving limited patient populations.

Beyond geographic expansion, the funding will support ongoing research, production scaling and development of Science Corporation's biohybrid brain interface initiative. This experimental program leverages cultured neurons to establish connections between electronic systems and brain tissue.

Source: The Next Web